Exacerbation of Bloody Diarrhea as a Side Effect of Mesalamine Treatment of Active Ulcerative Colitis [PDF]
Case Reports in Gastroenterology, 2011 Mesalamine has been used as the first-line therapy for the treatment of ulcerative colitis (UC) because of its efficacy and fewer side effects. However, earlier study showed that mesalamine occasionally causes diarrhea.
Yuichi Shimodate +5 more
doaj +8 more sources
Myocarditis Secondary to Mesalamine-Induced Cardiotoxicity in a Patient with Ulcerative Colitis [PDF]
Case Reports in Medicine, 2018 Development of cardiac manifestations in patients diagnosed with inflammatory bowel disease undergoing treatment with mesalamine is a rare. When this occurs, it can be difficult to tease out the primary etiology, as both IBD and mesalamine can cause ...
Kelechukwu U. Okoro +2 more
doaj +3 more sources
Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine [PDF]
Patient Preference and Adherence, 2009 Daniel B Zandman, Mark A PeppercornHarvard Medical School, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Mesalamine and its derivatives are effective and well-tolerated therapies for ...
Daniel B Zandman, Mark A Peppercorn
doaj +3 more sources
Clinical and Experimental Gastroenterology, 2009 Glen A Doherty, Mark A PeppercornCenter for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA, USAAbstract: 5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative ...
Glen A Doherty, Mark A Peppercorn
doaj +3 more sources
Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study [PDF]
Intestinal Research, 2016 Background/AimsThe therapeutic effect of mesalamine is considered to be dose-dependent; however, no consensus has been reached regarding the optimal doses for individual patients.
Yasuo Suzuki +4 more
doaj +1 more source
Use of new, once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis. Is there anything new under the sun? [PDF]
, 2009 5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents are commercially available, including azobond pro-drugs, as well as delayed- and controlled-release forms of mesalazine.
Lakatos, Péter László
core +2 more sources
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine [PDF]
, 2012 Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, may also develop.
Moss, Alan C., Nanda, Kavinderjit
core +1 more source
Successful management of HIV infection in a patient with ulcerative colitis; a case report [PDF]
Journal of Preventive Epidemiology, 2021 Human immunodeficiency virus (HIV) is an infectious disease that is rarely seen in ulcerative colitis patients. Both diseases commonly involve the colon.
Zain Majid +5 more
doaj +1 more source
Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. [PDF]
, 2015 Sofosbuvir and simeprevir are used for the treatment of chronic hepatitis C (HCV) genotype 1. Both drugs have been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% with sofosbuvir plus simeprevir, and 0% with simeprevir.
Jakab, Simona +4 more
core +1 more source
Gels, 2023 This research aims to develop a drug delivery system that effectively treats colitis while administering curcumin/mesalamine by coating alginate/chitosan beads with Eudragit® S-100 to target the colon. Beads were tested to determine their physicochemical
Eman J. Heikal +8 more
doaj +1 more source